Le Lézard
Classified in: Health
Subjects: CCA, PET, FVT

Heska Schedules Second Quarter 2018 Financial Results Conference Call for August 7, 2018


LOVELAND, Colo., July 18, 2018 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, plans to announce its second quarter 2018 financial results in a press release to be issued on Tuesday, August 7, 2018 before the market opens. The Company plans to host a conference call to discuss the results at 9 a.m. MT / 11 a.m. ET on the same day, Tuesday, August 7, 2018.

To access the conference call:

    From within the United States, please dial 1-888-394-8218

    From outside of the United States, please dial 1-323-701-0225

    Reference Conference ID: 9053418

The conference call will be webcast live from the Company's website on www.heska.com.

A telephonic replay of the conference call will be available beginning at 2 p.m. ET and continue through 11:59 p.m. ET on Tuesday, August 14, 2018.

To access the replay:

    From within the United States, please dial 1-844-512-2921

    From outside the United States, please dial 1-412-317-6671

    Reference Replay Pin Number: 9053418

The webcast will also be archived on www.heska.com for 90 days.

About Heska

Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products. Heska's business is composed of Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). CCA includes, primarily for canine and feline use, point of care laboratory testing instruments and supplies under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit www.heska.com.

 

SOURCE Heska Corporation


These press releases may also interest you

at 18:55
ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
ZYUS Life Sciences Corporation ("ZYUS" or the "Company") is pleased to announce that Brent Zettl, President and CEO of ZYUS, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May...

at 18:42
George Weston Limited Announces Election of Directors
George Weston Limited ("Weston" or the "Company") today announced that all of the nominee directors listed in its management proxy circular dated March 19, 2024, were elected as directors of the Company. The vote was conducted at the Company's...

at 18:41
Family Source Consultants' New Modern Client-Focused Office for Surrogacy Agency Set to Revolutionize Family-Building Services
Family Source Consultants, LLC, a leading provider of surrogacy, egg donation, and all third-party reproduction services, is excited to announce the grand opening of its new state-of-the-art office dedicated to enhancing the journeys of intended...

at 18:15
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024....

at 18:00
Denny's Canada invites guests to enjoy a sweet treat in support of women's health
In recognition of Mother's Day on May 12th, Denny's Canada is delighted to announce that they have partnered with Women's Health Collective Canada (WHCC) to host a special fundraiser. From May 7th to 12th, in participating stores across Canada, $2...

at 17:41
Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial...

More news about Health...


News published on and distributed by: